Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
|
N Engl J Med
|
2012
|
13.48
|
2
|
Improved overall survival in melanoma with combined dabrafenib and trametinib.
|
N Engl J Med
|
2014
|
5.65
|
3
|
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
|
J Clin Oncol
|
2012
|
2.45
|
4
|
Strategies for modern biomarker and drug development in oncology.
|
J Hematol Oncol
|
2014
|
1.89
|
5
|
The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.
|
P T
|
2013
|
1.68
|
6
|
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.
|
J Transl Med
|
2012
|
1.60
|
7
|
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy.
|
Biomed Res Int
|
2015
|
1.25
|
8
|
Pathways and therapeutic targets in melanoma.
|
Oncotarget
|
2014
|
1.17
|
9
|
Dabrafenib and its potential for the treatment of metastatic melanoma.
|
Drug Des Devel Ther
|
2012
|
1.16
|
10
|
B-Raf and the inhibitors: from bench to bedside.
|
J Hematol Oncol
|
2013
|
1.14
|
11
|
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.
|
Clin Cancer Res
|
2013
|
1.10
|
12
|
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.
|
Oncologist
|
2013
|
1.08
|
13
|
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.
|
Mayo Clin Proc
|
2014
|
1.06
|
14
|
Targeting the RAS oncogene.
|
Expert Opin Ther Targets
|
2013
|
1.02
|
15
|
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.
|
Ther Adv Med Oncol
|
2013
|
0.99
|
16
|
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications.
|
Oncotarget
|
2014
|
0.92
|
17
|
New combinations and immunotherapies for melanoma: latest evidence and clinical utility.
|
Ther Adv Med Oncol
|
2013
|
0.92
|
18
|
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.
|
Mol Cancer Ther
|
2014
|
0.92
|
19
|
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.
|
Front Oncol
|
2013
|
0.89
|
20
|
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
|
Lancet Oncol
|
2015
|
0.89
|
21
|
Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
|
Cancer Lett
|
2015
|
0.88
|
22
|
Combination therapies for the treatment of advanced melanoma: a review of current evidence.
|
Biochem Res Int
|
2014
|
0.86
|
23
|
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.
|
Cancer Manag Res
|
2014
|
0.81
|
24
|
Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.
|
Oncotarget
|
2015
|
0.81
|
25
|
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
|
Lancet Oncol
|
2016
|
0.80
|
26
|
Biologics in dermatology.
|
Pharmaceuticals (Basel)
|
2013
|
0.80
|
27
|
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
|
J Transl Med
|
2014
|
0.80
|
28
|
New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.
|
Drug Healthc Patient Saf
|
2014
|
0.77
|
29
|
Malignant Melanoma.
|
Healthcare (Basel)
|
2013
|
0.75
|
30
|
Evolving pharmacotherapies for the treatment of metastatic melanoma.
|
Clin Med Insights Oncol
|
2013
|
0.75
|